Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy

The IMpower010 and KEYNOTE-091 trials have demonstrated the benefit of adjuvant immunotherapy (IO) after chemotherapy (C+IO) in resected non-small cell lung cancer (NSCLC), including those with epidermal growth factor receptor gene (EGFR) mutation. Meanwhile, several studies have reported that EGFR-...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zichun, Zhang, Xuanye, Wang, Yuhong, Yu, Zhixin, Yang, Chunlong, Zhou, Yixin, Hong, Shaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582971/
https://www.ncbi.nlm.nih.gov/pubmed/37848260
http://dx.doi.org/10.1136/jitc-2023-007327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582971/
https://www.ncbi.nlm.nih.gov/pubmed/37848260
http://dx.doi.org/10.1136/jitc-2023-007327

Ejemplares similares